RSV F protein vaccine - Novavax

Drug Profile

RSV F protein vaccine - Novavax

Alternative Names: Respiratory syncytial virus fusion protein virus-like particle vaccine - Novavax; Respiratory syncytial virus vaccine - Novavax; RSV F recombinant nanoparticle vaccine; RSV F Vaccine; RSV F-protein nanoparticle vaccine; RSV VLP vaccine candidate - Novavax/University of Massachusetts Medical School; RSV-F; RSV-F nanoparticle protein micelle vaccine; RSV-F VLP vaccine - Novavax; Soluble respiratory syncytial virus fusion protein vaccine

Latest Information Update: 24 Mar 2017

Price : $50

At a glance

  • Originator Novavax
  • Class Protein-vaccines; Proteins; Respiratory syncytial virus vaccines; Synthetic vaccines; Viral vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Respiratory syncytial virus infections

Most Recent Events

  • 20 Jan 2017 Novavax initiates enrolment in a phase II trial for Respiratory syncytial virus infections (elderly) in Southern Hemisphere
  • 03 Jan 2017 Phase-III clinical trials in Respiratory syncytial virus infections (Prevention) in Argentina (IM) (NCT02624947)
  • 01 Jan 2017 Phase-II clinical trials in Respiratory syncytial virus infections (In the elderly, Prevention) in Australia (IM) (NCT03026348)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top